Issue link: https://viewer.e-digitaledition.com/i/1367011
Women's Health Research Leads to Real-World Results WITH A FOCUS on developing leading- edge therapies that improve patient outcomes, Penn State Health Milton S. Hershey Medical Center has become a regional referral center for polycystic ovarian syndrome (PCOS) and endo- metriosis. In the United States, it is estimated that approximately 6.5 million women of child-bearing years live with endometriosis, and as many as 5 million women have PCOS. Although challenges in diagnosis and treatment remain for both conditions, robust clinical trials and a multidisciplinary approach practiced by the team at Penn State Hea lth and Penn State College of Medicine have substantially increased understanding of how to better treat these disorders. BREAKTHROUGH RESEARCH IS CHANGING PCOS TREATMENTS GLOBALLY Richard Legro, MD, FACOG, Chair of the Department of Obstetrics and Gynecology at Penn State College of Medicine, is a leading force for women's health research. After joining Penn State Health in 1991, he established a PCOS program with a trained group of endocrinologists who specialize in PCOS. He also developed a research program. Funded by the National Institutes of Health (NIH), Dr. Legro's landmark studies have contributed to the development of new international and national guidelines in the treatment and diagnosis of PCOS, establishing Penn State Health as a leader in the field. "We've done studies related to fertility treatment, prevention of cardiovascular disease, treatment of prediabetes, and a number of lifestyle and pharmaceutical interventions to treat PCOS," Dr. Legro says. "We tried to guide how to best treat this disorder … to treat infertility and to prevent the development of diabetes and heart disease." A number of these studies have been published in the New England Journal of Medicine. One of the biggest and most inf luentia l studies was a randomized control trial that compared two medica- tions: a new aromatase inhibitor called letrozole and clomiphene to eva luate which medication was a more effective treatment for infertility in women with PCOS who are trying to conceive. The results showed that letrozole led to higher rates of ovulation and live births, a conclu- sion that has shifted the guidelines for treating infertility in PCOS. "Care-def ining, paradigm-shifting r e s e a r c h h a s b e en le d her e ," s a y s Sa m a nt h a But t s , M D, Ch ief of t he Division of Reproductive Endocrinology and Infertility at the Milton S. Hershey Medical Center, noting that PCOS is the most common cause of infertility due to irregular ovulation. "For a long time, we'd been using medical treatment to get women to ovulate to address their main barrier to infertility, but a lot of these treatments are only moderately effective, at best, and [women are] made to repeat treatments over and over again … [The letrozole study] was an incredibly important study." Additional research focused on PCOS and infertility have led to more ground- breaking outcomes: + Women w it h P C O S h ave h i g her chances of success with in vitro fer- tilization when they electively preserve their embryos. + We i g h t l o s s p r i or t o i n fe r t i l i t y therapy improves ovulation and preg- nancy rates. BY ELESA SWIRGSDIN iMPROVED DiAGNOSTiC TECHNiQUES AND TREATMENTS FOR WOMEN'S HEALTH CONDiTiONS CONTiNUE TO EVOLVE AT PENN STATE HEALTH. at Penn State Health and Penn State College of Medicine Samantha Butts, MD, MSCE, chief of the Division of Reproductive Endocrinology and Infertility at the Milton S. Hershey Medical Center. 0 8❱❱❱❱❱ C O V E R S T O R Y

